Massachusetts-based Luminopia landed an FDA De Novo for its virtual reality digital therapeutic focused on helping children improve amblyopia, commonly called lazy eye.
The therapy, called Luminopia One, is geared toward children living with the condition between the ages of 4 and 7 and is focused on improving their visual acuity. Children put on a VR headset and are then shown “therapeutically...
Today NovaSight, an Israeli digital eye treatment and assessment startup in the pediatric space, announced a clinical trial for its CureSight system, with the goal of achieving Food and Drug Administration 510(k) clearance.
CureSight presents a new treatment method for amblyopia, also known as lazy eye, that doesn’t require patching. The device trains the brain to use both eyes simultaneously...
International pharma giant Novartis announced this morning the acquisition of Amblyotech, a startup that combines 3D glasses and video game software to treat amblyopia, more commonly known as "lazy eye." The terms of the deal were not disclosed.
Novartis also said that it will be developing new games and kicking off a proof-of-concept study alongside major French video game publisher Ubisoft and...
This morning Slovenia-based startup AmblyoPlay released its new digital vision therapy platform aimed at helping individuals with amblyopia, commonly called “lazy eye.”
The subscription-based technology, which can be used by adults or kids, gamifies vision therapy for the patient. Users can earn rewards, which can be sent to their home. The platform also gives parents a chance to monitor their...
